WORLD-FIRST EXPERIMENTAL CANCER TREATMENT PAVES WAY FOR CLINICAL TRIAL
Nature Medicine has published a peer reviewed paper detailing the experimental glioblastoma cancer treatment developed by Professor Georgina Long AO, Medical Director of Melanoma Institute Australia, paving the way for a clinical trial to be conducted by researchers at The Brain Cancer Centre in Melbourne.
Professor Long used her expertise in immunotherapy and drew on melanoma science to devise, lead and administer the treatment, the first documented use of neoadjuvant triple immunotherapy in glioblastoma.
LATEST NEWS
14th Annual Melanoma Charity Ball themed ‘Night at the Carnival’
Guests at this year’s Amie St Clair Ball in Wagga Wagga will be welcomed to a ‘Night at the Carnival’ themed evening.
Raising funds and sparking life-saving conversations
Read more about the amazing initiatives organised by our wonderful community, which not only raise critical funds for research, but also generate life-saving awareness.
MIA awarded prestigious NHMRC grant
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
Addressing fear of cancer recurrence
A study has been released investigating the effectiveness of a Melanoma Care Program for patients with early-stage melanoma with varying degrees of fear of cancer recurrence after treatment of their primary melanoma.
Global accuracy of MIA risk tool predicting sentinel node metastasis
The extensive global use of MIA’s online tool for estimating the risk of nodal metastasis in newly diagnosed melanoma patients has prompted an international study to validate its accuracy & improve its precision across diverse populations worldwide.
Leading MIA researchers and clinicians share latest advances in Athens
MIA researchers and clinicians attended the World Congress of Melanoma, held in conjunction with the EADO Congress, in Athens.
MIA’s MISSION
ZERO DEATHS FROM MELANOMA
MIA will achieve its mission through 3 pillars of action: Research, Clinical Care & Education.
MIA conducts its research under 4 themes: Prevention, Risk & Clinical Detection – Early Melanoma – Advanced Melanoma – Supportive Care & Survivorship.
1300
It is estimated 1300 Australians will die from melanoma this year
30 mins
1 Australian is diagnosed with melanoma every 30 minutes
90%
If caught early 90% of melanomas can be cured by surgery
Age 20-39
Melanoma is the most common cancer affecting Australians aged 20 to 39
